We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ImmunityBio Inc | NASDAQ:IBRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.76% | 7.98 | 7.95 | 7.98 | 8.20 | 7.70 | 7.96 | 4,499,599 | 00:59:15 |
From May 2023 to May 2024
By Dean Seal
Shares of ImmunityBio rose after the company resubmitted a biological license application for its investigational bladder cancer treatment N-803.
The stock was up 11% at $1.44 in early trading. Shares have fallen 71% year-to-date.
The clinical-stage immunotherapy company said Monday that it resubmitted the application to the U.S. Food and Drug Administration.
The application is supported by the results of ImmunityBio's studies in bladder cancer, including a study published last November.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 23, 2023 10:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year ImmunityBio Chart |
1 Month ImmunityBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
